Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication
Open accessAbstract
BACKGROUND: Non-adherence to medication remains a major challenge in the long-term management of patients with schizophrenia. Next to lack of insight into the illness, adverse effects of antipsychotic drugs, cognitive deficits, poor therapeutic alliance, reduced quality of life, missing social support, and negative attitudes toward medication are predictors of non-adherence. This study examined potential correlations between attitudes toward antipsychotic drug therapy, subjective well-being, and symptom change in patients with chronic schizophrenia. METHODS: 30 patients with schizophrenia starting monotherapy with a new-generation antipsychotic were included into the study. The Drug Attitude Inventory (DAI) and the Subjective Well-being under Neuroleptic Treatment Scale, short form (SWN-K), were administered after 2, 4, and 12 weeks of treatment. At the same points in time and at baseline, psychopathological symptoms were rated by means of the Positive and Negative Syndrome Scale (PANSS), and functioning was assessed by means of the Global Assessment of Functioning Scale (GAF). Antipsychotic induced side effects were evaluated by using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. RESULTS: Study participants had a mean age of 37.5 ± 9.7 years, baseline symptoms were mild. The PANSS total score improved significantly from baseline to weeks 4 (p = .003) and 12 (p = .001), respectively. Neither the DAI total score nor the SWN-K total score changed significantly over the course of time. The severity of symptoms was not correlated with drug attitude at any time point but was negatively correlated with wellbeing at weeks 2 (r = -.419, p = .021) and 4 (r = -.441, p = .015). There was no significant correlation between DAI and SWN-K total scores at any time point. CONCLUSIONS: Next to showing that the DAI and the SWN-K measure different aspects of subjective experiences during antipsychotic treatment these findings emphasize the use of both instruments to optimize adherence to medication.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A negative attitude towards medication does not represent a symptom of psychotic disorders.
“This confirms the assumption that a negative attitude towards medication does not represent a symptom of psychotic disorders.”
From Patients’ perception of coercion with respect to antipsychotic treatment of psychotic disorders and its predictors (2021) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Diener, E. (1984) · Social indicators research series · doi:10.1007/978-90-481-2350-6_2 · Cited by 11,469 · see citing works
Diener, E. (1984) · Psychological Bulletin · doi:10.1037/0033-2909.95.3.542 · Cited by 11,023
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771 · see citing works
ФАКТОРЫ ПСИХОЛОГИЧЕСКОГО БЛАГОПОЛУЧИЯ ЛЮДЕЙ ПОЖИЛОГО ВОЗРАСТА
М.Р., Н., & С.И., Б. (2026) · CyberLeninK (CyberLeninka) · doi:10.60797/irj.2026.170.43 · Cited by 7,967 · see citing works
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · see citing works
Quality of life and pharmacoeconomics in clinical trials
Spilker, B. (1996) · DigitalGeorgetown (Georgetown University Library) · Cited by 1,862 · see citing works
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · see citing works
Global Assessment of Functioning
Hall, R. C. W. (1995) · Psychosomatics · doi:10.1016/s0033-3182(95)71666-8 · Cited by 1,099 · see citing works
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,027 · see citing works
Insight in schizophrenia: a meta-analysis
Mintz, A. R., Dobson, K. S., & Romney, D. M. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00316-x · Cited by 563 · see citing works
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520 · see citing works
Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs
Naber, D., Moritz, S., Lambert, M., Rajonk, F., Holzbach, R., Mass, R., Andresen, B., Frank, P., Rüdiger, H., Reinhard, M. A., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00166-3 · Cited by 349 · see citing works
Naber, D. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00017 · Cited by 309 · see citing works
Voruganti, L. N. P., Heslegrave, R. J., Awad, A. G., & Seeman, M. V. (1998) · Psychological Medicine · doi:10.1017/s0033291797005874 · Cited by 260 · see citing works
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn067 · Cited by 258 · see citing works
Medication adherence in schizophrenia
Acosta, F. J. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i5.74 · Cited by 215 · see citing works
Measuring Quality of Life in Patients with Schizophrenia
Awad, A. G., Voruganti, L. N. P., & Heslegrave, R. J. (1997) · PharmacoEconomics · doi:10.2165/00019053-199711010-00005 · Cited by 192 · see citing works
Awad, A. G., Voruganti, L. N. P., & Heslegrave, R. J. (1997) · Quality of Life Research · doi:10.1023/a:1026409326690 · Cited by 172 · see citing works
Measuring Quality of Life in Patients with Schizophrenia
Awad, A. G., & Voruganti, L. N. P. (2012) · PharmacoEconomics · doi:10.2165/11594470-000000000-00000 · Cited by 171 · see citing works
Lambert, M., SCHIMMELMANN, B. G., Naber, D., Schacht, A., Karow, A., Wagner, T., & Czekalla, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1104 · Cited by 169 · see citing works
Schizophrenia and quality of life
Katschnig, H. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.00006.x · Cited by 167 · see citing works
Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications
Freudenreich, O., Cather, C., Evins, A. E., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1012 · Cited by 141 · see citing works
Larsen, E. B., & Gerlach, J. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb10664.x · Cited by 136 · see citing works
Subjective well-being and quality of life under atypical antipsychotic treatment
Karow, A., & Naber, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1052-z · Cited by 135 · see citing works
Rettenbacher, M. A., Hofer, A., Eder, U., Hummer, M., Kemmler, G., Weiss, E. M., & Fleischhacker, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0908 · Cited by 126 · see citing works
Self-citationInsight in schizophrenia and its relationship to psychopathology
Kemp, R., & Lambert, T. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(95)00018-6 · Cited by 117 · see citing works
DAI-10 is as good as DAI-30 in schizophrenia
Nielsen, R. E., Lindström, E., Nielsen, J., et al. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.008 · Cited by 112 · see citing works
Attitudes Toward Antipsychotics Among Outpatient Clinic Attendees With Schizophrenia
Hofer, A., Kemmler, G., Eder, U., Honeder, M., Hummer, M., & Fleischhacker, W. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0110 · Cited by 100 · see citing works
Self-citationNeuroleptics and the neuroleptic‐induced deficit syndrome
Lewander, T. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05825.x · Cited by 97 · see citing works
Mas-Expósito, L., Amador, J. A., Gómez‐Benito, J., & Lalucat-Jo, L. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9847-1 · Cited by 87 · see citing works
Schizophrenia: Impact on quality of life
Singh, P., Solanki, R., Midha, A., et al. (2008) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.43632 · Cited by 78 · see citing works
Clinical Psychopharmacology and Neuroscience
Kim, C. H. (2017) · Cited by 65 · see citing works
Brain, C., Allerby, K., Sameby, B., Quinlan, P. S., Joas, E., Karilampi, U., Lindström, E., Eberhard, J., Burns, T., & Wærn, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.001 · Cited by 62 · see citing works
Lambert, M., Naber, D., Eich, F. X., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00862.x · Cited by 60 · see citing works
Lambert, M., Schimmelmann, B., Naber, D., Eich, F. X., Schulz, H., Huber, C. G., & Karow, A. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1234105 · Cited by 53 · see citing works
Vothknecht, S., Schoevers, R. A., & de Haan, L. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.545984 · Cited by 53 · see citing works
A comparative study on quality of life of patients of schizophrenia with and without depression
Dan, A., Kumar, S., Avasthi, A., & Grover, S. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.02.017 · Cited by 44 · see citing works
Subjective experiences on antipsychotic medications: synthesis and conclusions
Marder, S. R. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00544.x · Cited by 44 · see citing works
Lambert, M., SCHIMMELMANN, B. G., Schacht, A., Karow, A., Wagner, T., Wehmeier, P. M., Huber, C. G., Hundemer, H., Dittmann, R., & Naber, D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.035 · Cited by 44 · see citing works
Lambert, M., SCHIMMELMANN, B. G., Karow, A., et al. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45128 · Cited by 43 · see citing works
Hofer, A., Rettenbacher, M. A., Edlinger, M., Kemmler, G., Widschwendter, C. G., & Fleischhacker, W. W. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01087.x · Cited by 40 · see citing works
Self-citationPutzhammer, A., Perfahl, M., Pfeiff, L., et al. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-864125 · Cited by 38 · see citing works
Naber, D., Moritz, S., Lambert, M., Pajonk, F., Holzbach, R., Mass, R., & Andresen, B. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00319-x · Cited by 34 · see citing works
Wolters, H. A., Knegtering, H., van den Bosch, R. J., & Wiersma, D. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.026 · Cited by 33 · see citing works
The impact of subjective well-being under neuroleptic treatment on compliance and remission
de Millas, W., Lambert, M., & Naber, D. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/wmillas · Cited by 27 · see citing works
Treatment with neuroleptics: the patient's perspective
Windgassen, K. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03288.x · Cited by 23 · see citing works
Hosseini, S. H., & Yousefi, M. K. (2011) · PubMed · Cited by 16 · see citing works
Schennach-Wolff, R., Seemüller, F., Obermeier, M., Messer, T., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L., Gäebel, W., Klosterkötter, J., et al. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.11.005 · Cited by 15 · see citing works
Wehmeier, P. M., Kluge, M., Schacht, A., Helsberg, K., Schreiber, W., SCHIMMELMANN, B. G., & Lambert, M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.07.005 · Cited by 15 · see citing works
Mauri, M., Mauri, M. C., Adami, M., Reggiardo, G., & Corrivetti, G. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000092 · Cited by 10 · see citing works
Compliance with treatment and its relevance for the management of schizophrenia
Hofer, A., & Fleischhacker, W. W. (2012) · Hot Topics in Neurology and Psychiatry · doi:10.4147/htn-111107 · Cited by 8 · see citing works
Self-citationLee, Y.-W., Kim, J., Ann, J.-H., et al. (2010) · Clinical Psychopharmacology and Neuroscience · Cited by 6 · see citing works
Attitudes Toward Medications and the Relationship to Outcomes in Patients with Schizophrenia
Campbell, A. H., Scalo, J., Crismon, M. L., et al. (2015) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.casc.070415 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [35]Hofer A Kemmler G Eder U Honeder M Hummer M Fleischhacker WW Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia J Clin Psychiatry. 2002 63 1 49 53 10.4088/JCP.v63n0110 11838626 · DOI
Cited by
Sorted by citations
Hirsch, S., Thilo, N., Steinert, T., & Flammer, E. (2021) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-021-02083-z · Cited by 9 · see citing works
- Authors
- Widschwendter, C. G., Kemmler, G., Rettenbacher, M. A., Yalcin-Siedentopf, N., & Hofer, A.
- Affiliations
- Innsbruck Medical University (AT)
- Corresponding author
- Widschwendter, Christian G.
- Venue
- BMC Psychiatry
- Published
- 2018-06-28
- Volume
- 18
- Issue
- 1
- Pages
- 212-212
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC6022409
- OpenAlex
- W2810771352
- Cited by
- 18
- References
- 54
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 3
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- chronic schizophrenia, subjective well-being, attitudes toward drugs, antipsychotic adherence, symptom change, antipsychotic adverse effects, Drug Attitude Inventory, PANSS, Global Assessment of Functioning
- MeSH terms
- Adult, Attitude, Chronic Disease, Female, Humans, Male, Middle Aged, Quality of Life, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
